Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Robo4 molecule may improve bone marrow transplants: Study

Robo4 molecule may improve bone marrow transplants: Study

Students donate $6.1 million for cancer research

Students donate $6.1 million for cancer research

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

EUSA receives FDA Priority Review status for ERWINAZE BLA

EUSA receives FDA Priority Review status for ERWINAZE BLA

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

EpiCept regains compliance with continued listing requirement of Nasdaq Capital Market

EpiCept regains compliance with continued listing requirement of Nasdaq Capital Market

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

Researchers identify new regulator that play a critical role in B cell development

Researchers identify new regulator that play a critical role in B cell development

GE Healthcare announces completion of tender offer for Clarient

GE Healthcare announces completion of tender offer for Clarient

Research: Arsenic trioxide may benefit individuals with connective brain tumors

Research: Arsenic trioxide may benefit individuals with connective brain tumors

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

People with high RBC folate levels more likely to have two tumor-suppressing genes

People with high RBC folate levels more likely to have two tumor-suppressing genes

Therapies to target self-renewing population of chemotherapy-resistant cells needed

Therapies to target self-renewing population of chemotherapy-resistant cells needed

High LSC scores associated with adverse outcomes in AML patients

High LSC scores associated with adverse outcomes in AML patients

Chronic fatigue syndrome not linked to virus

Chronic fatigue syndrome not linked to virus

Study: Chemotherapy can improve survival rate in older adolescents with leukemia

Study: Chemotherapy can improve survival rate in older adolescents with leukemia

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.